Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Dilated cardiomyopathy relieved as a result of β-blocker therapy: A case report—key points in assessment of prognosis based on MIBG myocardial scintigraphy and BNP levels

Abstract

A 48-year-old male patient was admitted to our hospital with dyspnea accompanied by orthopnea. Chest x-rays showed a cardiothoracic ratio of 68% and pulmonary congestion. He was diagnosed with dilated cardiomyopathy. β-Blocker (Carvedilol) therapy was initiated on Day 22 of the disease using a small initial dose. He was followed up based on BNP levels and MIBG scintigraphy. The H/M ratio and MIBG washout rate were 1.98 and 33.4%, respectively, on. Day 20 and 2.15 and 28.1%, respectively, on Day 72. The patient was discharged on Day 72 when congestive heart failure improved. Relatively high BNP levels were observed for 1 month after starting treatment with a β-blocker. Plasma BNP levels were still as high when his heart failure was improved. BNP is useful as a convenient indicator for the severity of cardiac diseases. MIBG scintigraphy may be used thereafter to evaluate the severity in greater detail and more precisely determine the prognosis.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Cohn JN, Levine TB, Olivari MT, et al. Plasma norepineph-rine as a guide to prognosis in patients with heart failure.N Engl J Med 1984; 311: 819–823.

  2. 2.

    Merlet P, Valette H, Dubois RJ, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.J Nucl Med 1992; 33 (4): 471–477.

  3. 3.

    Matsuo S, Nakamura Y, Matsumoto T, Nakae I, Takada M, Murata K, et al. Prognostic value of Iodine-123 metaiodobenzylguanidine imaging in patients with heart failure.Exp Clin Cardiol 2003; 8 (2): 95–98.

  4. 4.

    Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure.J Am Coll Cardiol 2004; 43 (4): 635–641.

  5. 5.

    Matsuo S, Takahashi M, Nakamura Y, Kinoshita M. Evaluation of cardiac sympathetic innervation with iodine-123-metaiodobenzylguanidine imaging in patients with silent myocardial ischemia.J Nucl Med 1996; 37: 712–717.

  6. 6.

    Matsuo S, Nakamura Y, Takahashi M, Matsui T, Kusukawa J, Yoshida S, et al. Cardiac sympathetic dysfunction in athlete’s heart detected by123IMIBG scintigraphy.Jpn Circ 72001; 65 (5): 371–374.

  7. 7.

    Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy.Circulation 1993; 88 (2): 372–380.

  8. 8.

    Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic Peptides to left ventricular geometric patterns in essential hypertension.Am J Hypertens 1999; 12 (9 Pt 1): 921–924.

  9. 9.

    Silvet H, Young-Xu Y, Walleigh D, Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation.Am J Cardiol 2003; 92 (9): 1124–1127.

  10. 10.

    Matsuo S, Nakamura Y, Kinoshita M, Hone M. Plasma B-type natriuretic peptide measurement in asymptomatic population.International Medical Journal 2003; 10 (2): 105–108.

  11. 11.

    Fung JW, Yu CM, Yip G, Chan S, Yandle TG, Richards AM, et al. Effect of beta blockade (Carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure.Am J Cardiol 2003; 92 (4): 406–410.

  12. 12.

    Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy—Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography.Am Heart J 2001; 141 (4): 645–652.

  13. 13.

    Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.Eur J Nucl Med Mol Imaging 2005; 32 (2): 186–194.

  14. 14.

    Matsuo S, Nakamura Y, Matsui T, Matsumoto T, Kinoshita M. Detection of denervated but viable myocardium in cardiac sarcoidosis with 1-123 MIBG and Tl-201 SPECT Imaging.Ann Nucl Med 2001; 15: 373–375.

  15. 15.

    Matsuo S, Nakamura Y, Matsumoto T, Takahashi M, Kinoshita M. Detection of coronary microvascular disease by means of cardiac scintigraphy.Can J Cardiol 2002; 18 (2): 183–186.

  16. 16.

    Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M. Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hyper-trophic cardiomyopathy.J Nucl Cardiol 2002; 9 (4): 407–412.

  17. 17.

    Matsuo S, Nakae I, Takada M, Murata K, Nakamura Y. Noninvasive identification of myocardial sympathetic and metabolic abnormalities in a patient with restrictive cardiomyopathy —in comparison with perfusion imaging—.Ann Nucl Med 2002; 16 (8), 569–572.

  18. 18.

    Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K; Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123-metaiodobenzyl-guanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy.Jpn Circ J 2001; 65 (3): 155–160.

  19. 19.

    Matsuo S, Matsumoto T, Nakae I, Koh T, Masuda D, Takada M, et al. Prognostic value of ECG-gated thallium-201 single-photon emission tomography in patients with coronary artery disease.Ann Nucl Med 2004; 18 (7): 617–622.

Download references

Author information

Correspondence to Shinro Matsuo or Ichiro Nakae or Daisuke Masuda or Tetsuya Matsumoto or Minoru Horie.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Matsuo, S., Nakae, I., Masuda, D. et al. Dilated cardiomyopathy relieved as a result of β-blocker therapy: A case report—key points in assessment of prognosis based on MIBG myocardial scintigraphy and BNP levels. Ann Nucl Med 19, 243 (2005). https://doi.org/10.1007/BF02984613

Download citation

Key words

  • MIBG
  • BNP
  • prognosis
  • heart failure